Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.

by Joel Raffel, Arie R Gafson, Samer Dahdaleh, Omar Malik, Brynmor Jones, Richard Nicholas
Published 2017-01-01

Remote Monitoring in the Home Validates Clinical Gait Measures for Multiple Sclerosis

by Akara Supratak, Gourab Datta, Arie R. Gafson, Richard Nicholas, Richard Nicholas, Yike Guo, Paul M. Matthews, Paul M. Matthews, Paul M. Matthews, Paul M. Matthews
Published 2018-07-01